Evommune nabs $150M in IPO amid federal shutdown

BioPharma Dive Oncology | |

<figure><div><img src="https://imgproxy.divecdn.com/fVZ07SHmyWbYfMeCN9JOs5HMBgNiMU3cPGrhWFX8ung/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy01MDQ1MjI4NTAuanBn.webp" /></div></figure><p>The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities law to price an offering during the shutdown.&nbsp;</p>

Topics: oncology